Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 11;14(11):e0008838.
doi: 10.1371/journal.pntd.0008838. eCollection 2020 Nov.

The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia

Kamala Thriemer  1 , Jeanne-Rini Poespoprodjo  2   3   4 , Enny Kenangalem  3   4 , Nicholas M Douglas  1   5 , Paulus Sugiarto  6 , Nicholas M Anstey  1 , Julie Anne Simpson  7 , Ric N Price  1   8   9
Affiliations

The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia

Kamala Thriemer et al. PLoS Negl Trop Dis. .

Abstract

The widespread use of primaquine (PQ) radical cure for P. vivax, is constrained by concerns over its safety. We used routinely collected patient data to compare the overall morbidity and mortality in patients treated with and without PQ without prior testing of Glucose-6-Phosphate-Dehydrogenase (G6PD) deficiency in Papua, Indonesia, where there is a low prevalence of G6PD deficiency. Records were collated from patients older than 1 year, with P. vivax infection, who were treated with an artemisinin combination therapy (ACT). The risks of re-presentation, hospitalization, major fall in haemoglobin and death within 30 days were quantified and compared between patients treated with and without PQ using a Cox regression model. In total 26,216 patients with P. vivax malaria presented to the hospital with malaria during the study period. Overall 27.56% (95% Confidence Interval (95%CI): 26.96-28.16) of 21,344 patients treated with PQ re-presented with any illness within 30 days and 1.69% (1.51-1.88) required admission to hospital. The corresponding risks were higher in the 4,872 patients not treated with PQ; Adjusted Hazard Ratio (AHR) = 0.84 (0.79-0.91; p<0.001) and 0.54 (0.41-0.70; p<0.001) respectively. By day 30, 14.15% (12.45-16.05) of patients who had received PQ had a fall in haemoglobin (Hb) below 7g/dl compared to 20.43% (16.67-24.89) of patients treated without PQ; AHR = 0.66 (0.45-0.97; p = 0.033). A total of 75 (0.3%) patients died within 30 days of treatment with a mortality risk of 0.27% (0.21-0.35) in patients treated with PQ, compared to 0.38% (0.24-0.60) without PQ; AHR = 0.79 (0.43-1.45; p = 0.448). In Papua, Indonesia routine administration of PQ radical cure without prior G6PD testing, was associated with lower risk of all cause hospitalization and other serious adverse clinical outcomes. In areas where G6PD testing is not available or cannot be delivered reliably, the risks of drug induced haemolysis should be balanced against the potential benefits of reducing recurrent P. vivax malaria and its associated morbidity and mortality.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Study Profile.
Fig 2
Fig 2. Risk of all cause re-presentation by primaquine (PQ) dose.
Fig 3
Fig 3. Risk of all cause hospitalization by primaquine (PQ) dose.
Fig 4
Fig 4. Risk of all cause death by primaquine (PQ) dose.
See this image and copyright information in PMC

References

    1. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of Plasmodium vivax malaria. Malaria journal. 2012;11:135 10.1186/1475-2875-11-135 - DOI - PMC - PubMed
    1. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends in parasitology. 2020;36(6):560–70. 10.1016/j.pt.2020.03.009 . - DOI - PMC - PubMed
    1. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends in parasitology. 2009;25(5):220–7. 10.1016/j.pt.2009.02.003 . - DOI - PubMed
    1. White MT, Shirreff G, Karl S, Ghani AC, Mueller I. Variation in relapse frequency and the transmission potential of Plasmodium vivax malaria. Proc Biol Sci. 2016;283(1827):20160048 10.1098/rspb.2016.0048 - DOI - PMC - PubMed
    1. Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malaria journal. 2017;16(1):141 10.1186/s12936-017-1784-1 - DOI - PMC - PubMed

Publication types

MeSH terms